Skip to main content
2025 Canadian Cardiovascular Congress Main banner

G.B. John Mancini, MD, FRCPC, FACC (he/him/his)

Cardiologist
Centre for Cardiovascular Innovation, Dilawri Cardiovascular Institute, University of British Columbia
University of British Columbia

Dr. Mancini received his MD degree from the University of Toronto (1977), did his residency at St. Michael’s and Toronto General Hospitals and was a Cardiology and Research Fellow at the University of California at San Diego. After a year in the rank of Clinical Assistant Professor at U.C. San Diego, he joined the faculty of the University of Michigan in 1983 where he achieved the rank of tenured Professor and Chief of the V.A. Section of Cardiology and Associate Chief of the University of Michigan, Division of Cardiology. He became Chair of Medicine at the University of British Columbia, 1992-2002. Dr. Mancini is a member of the Centre for Cardiovascular innovation and the Dilawri Cardiovascular Institute.

Dr. Mancini remains a tenured Professor of Medicine at the University of British Columbia and directs an imaging-based research program (Cardiovascular Imaging Research Core Laboratory, CIRCL) that includes facilities for quantitative coronary angiography, ultrasound analyses (coronaries, carotids and brachial artery for atherosclerosis and endothelial function assessments) and cardiac computed tomography. This program has been actively funded for over 30 years, originating at the University of Michigan and transferred to UBC in 1992. Dr. Mancini’s interest focuses on the integration of multi-modality cardiac imaging in multicenter clinical trials for assessment of structural and functional aspects of coronary atherosclerosis and for primary and secondary cardiovascular risk reduction. He has published over three hundred journal articles, abstracts, books and book chapters.

Dr. Mancini remains the Scientific Director of CardioRisk Clinic which fosters innovation in novel CV risk detection and therapy, to support FH Canada for the identification and treatment of patients with Familial Hypercholesterolemia and to support the SAVE BC program to identify patients and families with very early atherosclerotic heart disease in order to understand the causes and identify novel risk factors.

Disclosure information not submitted.

Presentation(s):